Highlights of the call:

On Consolidated basis, The Revenues grew by 18% YoY to Rs 1202.5 crore for the quarter ended June 2014. However, The EBIDTA margins fell by 130 bps YoY to 14.4% and after this EBIDTA grew by 8% YoY to Rs 173.1 crore during the quarter. Further, PAT grew by mere 2% YoY to Rs 79.5 crore for the same period.

On Standalone basis, The Revenues grew by 18% YoY to Rs 1053.7 crore for the quarter ended June 2014 and PAT grew by 5% YoY to Rs 82.7 crore for the same period.

The Revenues from the Chennai cluster grew by 8% YoY to Rs 288.7 crore for the quarter ended June 2014. Also, The Hyderabad Revenues grew by 11% YoY to Rs 120.4 crore during the quarter.

The Vangaram hospital in Chennai witnessed impressive good growth during the quarter.

The Hyderabad cluster has reported improvement in occupancy of 603 beds (65 % utilization on beds) in Q1FY15 as compared to 592 beds (64%) in Q1FY14. More importantly, the cluster witnessed EBITDA expansion aided by higher numbers of international patients, focused efforts on case mix rationalization, growth in robotics and transplants as well as cost management.

The Others Hospitals are driving substantial growth (21.6%) during the quarter. This is due to focus on Inpatient revenue growth (22.6%). Also, there is 16.3% growth in OP Revenues driven by Volumes in Bhubaneswar, Jayanagar Bilaspur, Vizag & Mysore.

The Bhubaneswar occupancy at 208 beds (81% utilization on capacity of 256 beds) as compared to 202 beds in Q1FY14. The Q1FY15 EBITDA margins at 22% from 21% in the same period last year.

The Revenue growth from Significant Subsidiary / JV & Associates Hospitals is 12.5% YoY during the quarter. There is over 15% yoy growth in Kolkata and Ahmedabad Hospitals during the quarter.

The FY13 New Hospitals - Vanagaram & Jayanagar displayed good traction. The Revenues of these hospitals grew from Rs 7.5 crore to Rs 28.1 crore in Q1FY15.

The FY14 Hospitals ¨C Trichy & Nashik still in the initial stages of operations and reported revenue of Rs 4.3 crore during the quarter.

The New Hospitals in initial stages of operations reported operating loss of Rs 1.6 crore during the quarter. The AHLL reported an EBITDA loss of Rs 4.8 crore due to addition of 2 birthing centers and new Clinics during the quarter.

The Rationalization of the case mix led to a dip in occupancy at Madurai. However, Revenues witnessed a marginal growth accompanied by an improvement in the EBITDA margin.

In Chennai cluster volume growth is muted due to the rebalancing which impacted the quarter. However, it expects volumes to pick-up going forward.

In general increase the tariffs in the Chennai cluster in the Q1 but increased this and will increase at the appropriate time, which has impacted the ARPOB during the quarter.

During the quarter, the increased impact in Depreciation due to application of higher depreciation rates as per the New Companies Act coupled with the New Units ¨C Trichy & Nashik.

The aim is to keep the healthcare Margins at 23-24% going forward. The Chennai cluster margins are higher and want to focus on the Hyderabad cluster (20-21% now) going forward.

The Navi Mumbai project will take another 8 months to operationalize. The byculla project some delays and in the next 5 months some work there. It believes ARPOB in Mumbai will be higher than the Chennai.

The lower occupancies in Hospitals due to the Election in the April and May during the quarter.

During the quarter, Apollo Pharmacies added 53 stores and closed 21 stores for a net addition of 32 stores. The total store network as of June 30 stands at 1,664 operational stores.

The Revenues from Pharmacy business grew by 27% from Rs 386.2 crore for the quarter ended June 2014. The Operational performance improved further as EBITDA grew by 33% to Rs 12 crore during the quarter.

The blended EBITDA margins are increased by 14 basis points from 2.97% in Q1FY14 to 3.11% in Q1FY15. The increasing proportion of Private label products in the revenue mix has helped to mitigate the impact of the Drug Price Control Order.

The business continued to report healthy growth in same©\store sales across various batches of stores with like©\for©\like growth in revenue per store at 14% for the pre 2008 batch of stores, 21% (2009 batch) and 18% (2010 batch). The EBITDA margin for mature stores (pre March 2008) expanded by 25 basis points from 5.6% in Q1FY14 to 5.8% in Q1FY15.

The Company is on track to commission 3 Hospitals in Q2FY15 - Nellore (200 beds) and 2 hospitals in Chennai OMR- Perungudi (170 beds) and Chennai OMR - Women & Child (45 beds).

It plans to operationalize the 1000 beds in the current fiscal. It plans to add 600 beds in the Nellore, Nasik and Vizag by the end of 6 months and also to operationalize another 300 beds in Chennai, and 125 beds in Indore.

It Plans to add 10 hospitals from the current 41(owned) with addition of 2,065 beds to the current owned bed capacity of 6,932 (owned) by FY¡¯17. The Apollo has already invested Rs 658.6 crore of the Rs 2009.7 crore of its share of total capex as on Jun 30, 2014